Denali Therapeutics Conference Call Summary Company Overview - **Company**: Denali Therapeutics (NasdaqGS:DNLI) - **Focus**: Development of medicines for neurological diseases using transferrin receptor-enabled technologies Key Points Upcoming Milestones - Denali has a **PDUFA date** set for **April 5, 2026**, for its lead program, **tividenofusp alfa (Tivi)**, aimed at treating **Hunter syndrome** [3][6] Clinical Data and Regulatory Interaction - Tivi was developed starting in **2020**, with early data showing that **4 out of 5 patients** had normalized heparan sulfate after **4 doses**, indicating the platform's effectiveness [3][4] - Denali's **BLA submission** was completed last year, and interactions with the **FDA** have been described as constructive, with no further questions on the CMC aspect [5][11] - The company is in the final stages of label discussions and post-marketing commitments [11] Competitive Landscape - Denali is aware of the recent **CRL** received by **REGENXBIO** and believes its own dataset, which includes **47 patients** treated for up to **4-5 years**, positions it strongly for approval [18][19] - Denali's data shows normalization of heparan sulfate and neurodegeneration biomarkers (NfL), which are critical for demonstrating clinical benefit [18][19] Comparison with Standard of Care - The current standard of care for Hunter syndrome is **idursulfase**, which has been in use for nearly **20 years**. Denali's Tivi is engineered to cross the blood-brain barrier, potentially benefiting the **70%** of patients with severe neurological deficits [32][33] - Data indicates that patients switching from idursulfase to Tivi show improved biomarker outcomes, supporting a **switch strategy** for physicians [41][42] Commercial Strategy - Denali has built its field team and engaged with payers and centers of excellence to prepare for the launch of Tivi [35][36] - The company expects strong uptake among newly diagnosed patients and those with severe neurological manifestations [36] Genetic Testing and Newborn Screening - Genetic testing is required for an official diagnosis of Hunter syndrome, and **13 states** in the U.S. have adopted newborn screening, which is expected to increase with the approval of new medicines [46][52] Financial Strategy - Denali's deal with **Royalty Pharma** is aimed at strengthening its financial position, allowing it to fund its goals through **2028** [53] Pipeline Developments - Denali is also advancing its program for **Sanfilippo syndrome (DNL126)**, with promising data on biomarker reductions and plans for a BLA filing using CSF heparan sulfate as a surrogate endpoint [57][58] - The company is preparing to begin dosing for its **Pompe program** using the Transport Vehicle technology, which aims to improve muscle and brain biodistribution [69][70] Future Programs - Denali is developing **MAPT** and **Abeta** programs targeting Alzheimer's disease, with plans to start clinical studies soon [82][87] - The **LRRK2** program is also in progress, focusing on a kinase associated with Parkinson's disease, with enrollment nearing completion [101][107] Differentiation in Technology - Denali emphasizes its unique approach to blood-brain barrier penetration, having developed a modular system that allows for various therapeutic applications, including oligonucleotides [76][77] Conclusion - Denali Therapeutics is positioned for significant advancements in the treatment of neurological diseases, with a strong pipeline and a focus on innovative delivery mechanisms that could redefine standards of care in the field [112][113]

Core Insights - The company is preparing for a busy 6 to 9 months ahead, focusing on key clinical developments and transitions [2] Group 1: Clinical Developments - The company plans to bring MAPT, its first CNS drug administered via subcutaneous injection, to the clinic [2] - Following MAPT, the company will introduce its first dimer, the PCSK9 APOC3 dimer, which is expected to be a significant tool against atherosclerotic cardiovascular disease (ASCVD) [2] Group 2: Regulatory and Data Milestones - A major event is the PDUFA date for plozasiran in November, marking a transition from an R&D-only company to one that is also commercial [3] - The company anticipates data releases for INHBE and ALK7 related to obesity, with additional ALK7 data expected in the first half of 2026, approximately 6 months behind INHBE in dosing [3]

Summary of Arrowhead Pharmaceuticals (ARWR) Conference Call Company Overview - **Company**: Arrowhead Pharmaceuticals (ARWR) - **Event**: 2025 Conference at Cantor's Global Healthcare Conference - **Date**: September 04, 2025 Key Priorities and Upcoming Events - **MAPT Clinical Trial**: Launching the first CNS drug administered via subcutaneous injection [3] - **PCSK9 ApoC3 Dimer**: Expected to enter the clinic, targeting ASCVD [4] - **Blazaran PDUFA Date**: Scheduled for November, marking a transition to a commercial company [4] - **Data Releases**: Anticipated data on MAPT and dimer by mid-2026 [5] Regulatory and Commercial Strategy - **Regulatory Interactions**: Positive discussions with regulators, no slowdown reported [6] - **Commercial Preparations**: Commercial team fully established and in training for FCS launch in November [7] Competitive Landscape - **SHTG Market**: Acknowledgment of competitor data, emphasizing the importance of education in the market [8] - **Pricing Strategy**: Discussion on pricing for Plazasiran, suggesting it may be higher than typical cardiovascular drugs due to its unique application [9][10] Clinical Trials and Data Expectations - **Shasta Trials**: Focused on triglyceride lowering, with Shasta-five designed to show effects on pancreatitis [11][12] - **Market Addressability**: Targeting patients with triglycerides above 800, estimated at one million in the U.S. [17][18] Product Differentiation - **Efficacy Comparison**: Plazasiran showed an 80% reduction in triglycerides compared to a competitor's 40% [23] - **Safety Profile**: Claims of superior safety and less frequent dosing compared to competitors [23] Obesity Portfolio - **Dual Targets**: ALK7 and Inhibin E targeting the activin pathway, with potential for both to advance based on clinical data [34] - **Market Positioning**: Potential for use as monotherapy or in combination with GLP-1s for obesity treatment [38] Business Development and Partnerships - **Partnership Strategy**: Focus on maintaining wholly owned assets while exploring partnerships for non-core assets [42][45] - **Recent Deal with Novartis**: $200 million upfront for a preclinical asset, indicating strong interest in CNS applications [46] Financial Outlook - **Cash Runway**: Sufficient cash to sustain operations until 2028, with expectations for further business development [59] Conclusion - Arrowhead Pharmaceuticals is positioned for significant developments in the CNS and metabolic disease markets, with a clear strategy for clinical trials, regulatory interactions, and commercial preparations. The company is focused on leveraging its innovative drug delivery platforms and maintaining a competitive edge through effective differentiation and strategic partnerships.